LEIDEN, Netherlands--(BUSINESS WIRE)--to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, today announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V. Dr. Ferdinand (Ferd) Massari and Dr. Pericles (Perry) Calias have joined BBB as Chief Medical Officer and as Chief Scientific Officer, respectively. Completing the management team are recently appointed Chief Executive Officer Dr. Anders Harfstrand, and Chief Financial Officer Leon Kruimer and Chief Business Officer Dr. Carlos de Sousa, both of whom joined the company in January of 2014.
Dr. Harfstrand, CEO, comments: "Both Ferd and Perry solidify BBB's commitment to providing therapeutic solutions in neuro-oncology, most importantly demonstrating clinical proof of concept for 2B3-101, our lead compound to treat metastatic brain tumors, scheduled to complete a Phase 2 trial in a few months. Ferd´s substantial experience in all aspects of clinical development and successful interaction with regulatory authorities all over the world will be instrumental to the further development of 2B3-101. Likewise, Perry's unique expertise in pre-clinical development including intellectual property will be invaluable for the further advancement of our pipeline."
"Through these important management additions, BBB Therapeutics has transitioned to a development-focused, clinical stage company nearing a significant inflection point in treating severe diseases of the brain," adds Patrick Krol, Chairman of the Supervisory Board and Managing Partner at Aescap Venture. "This advance is represented in the company's new name and highly focused strategy."
Dr. Ferd Massari brings over 25 years of experience in the pharmaceutical industry to the company. He joins BBB Therapeutics from ImmusanT, where he most recently acted as Senior Vice President and Chief Medical Officer. Dr. Massari has held leadership positions in numerous companies including Merck, Pharmacia, Pfizer, and Shire HGT. Dr. Massari holds an M.D. from Jefferson Medical College of Thomas Jefferson University and trained in immunology at the National Institute of Allergy and Infectious Diseases, NIH (US). His expertise extends to clinical research, regulatory affairs as well as marketing. He has successfully achieved a number of product registrations worldwide.
Dr. Perry Calias has been serving as Senior Vice President Translational Medicine for to-BBB since June 2014. Before this, he was a Senior Director for Shire HGT, where he led research and development efforts for innovative central nervous system delivery technologies. He has overseen the research contributions in regulatory filings both within the US and abroad, resulting in three clinical trials and several published peer-reviewed articles. Prior to Shire, he has held various R&D positions at EyeGate Pharmaceuticals, Eyetech Pharmaceuticals, Draper Laboratories, and Genzyme Corporation. Dr. Calias is listed as an inventor on over 30 domestic and foreign patents/applications spanning 18 different patent families.
BBB Therapeutics is pioneering advanced and innovative treatment options for severe brain disorders for which there are currently limited treatment options. Initially, the Company's focus will be on treating brain metastases and primary brain tumors. BBB Therapeutics has enrolled more than 80 patients in clinical trials for its neuro-oncology lead product candidate, 2B3-101. The Company also has generated promising safety data for its candidate 2B3-201, indicated for neuroinflammatory diseases, including Multiple Sclerosis acute relapses, optic neuritis and uveitis.
About BBB Therapeutics
BBB Therapeutics is developing medicines for the treatment of devastating brain diseases. Our proprietary liposomal G-Technology® facilitates entry to the brain while simultaneously enabling sustained delivery of systemically administered therapeutics. Our technology has been shown to be compatible with approved as well as novel therapeutic entities. We have two clinical programs targeting multiple indications in neuro-oncology and neuroinflammatory diseases.